Sino Biopharmaceutical Subsidiary Secures NMPA Approval for IM-101 Therapeutic Vaccine in Chronic Hepatitis B
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited (HKG:...
OrbusNeich Enrolls First Patient in Pivotal Japanese Trial for Proprietary Drug-Coated Balloon
OrbusNeich Medical Group Holdings Limited (HKG: 6929) announced the successful enrollment of the first patient...
Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma
Summit Therapeutics Inc. (NASDAQ: SMMT), in partnership with Akeso, Inc. (HKG: 9926), announced a strategic...
Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring
Former President Donald Trump announced on July 21, 2026 a three-phase tariff policy on generic...
GSK Secures Early FDA Approval for Jideytro – ROS1 Inhibitor for Resistant Non-Small Cell Lung Cancer
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced on July 22, 2026 that the U.S. Food and...
Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer
Pfizer Inc. (NYSE: PFE) announced on July 22, 2026 that the U.S. Food and Drug...
Ribo Life Science Reports Positive Phase 2a Results for Vortosiran in Chronic Coronary Artery Disease
Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced positive results from a Phase 2a...
Johnson & Johnson Secures FDA De Novo Authorization for OTTAVA™ – World’s First Table-Integrated Robotic Surgical System
Johnson & Johnson (NYSE: JNJ) announced on July 22, 2026 that the U.S. Food and...
Guangdong Launches Greater Bay Area Cross-Border Medical Import Framework for Hong Kong and Macau Pharmaceuticals
The Guangdong Provincial Drug Administration and Guangdong Provincial Health Commission have issued the Guidelines for...
China Announces 12th National Drug Volume-Based Procurement with Enhanced Pricing Mechanism and Expanded Participation
The National Joint Procurement Office announced on July 22, 2026 that the 12th batch of...
Haisco Pharma Secures NMPA Approval for HSK39297 – First Oral CFB Inhibitor for Paroxysmal Nocturnal Hemoglobinuria in China
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that China’s National Medical Products Administration (NMPA)...
Takeda Secures World’s First NMPA Approval for Orexatone – Novel Oral OX2R Agonist for Type 1 Narcolepsy
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that China’s National Medical Products Administration...
Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II
Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607, SHA: 601607) announced a RMB 300 million (approximately...
TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal
TYK Medicines (HKG: 2410) and Qilu Pharmaceutical announced a comprehensive strategic partnership comprising three agreements:...
Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications
Youcare Pharmaceutical (SHA: 688658) announced that its investigational compound YKYY033 has received clinical trial approval...
Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody
Trinomab Biotechnology Co., Ltd. (SHA: 688806) officially listed on the Science and Technology Innovation Board...
Novo Nordisk Sues Eli Lilly Over Alleged False Advertising of Zepbound and Mounjaro in GLP-1 Market
Novo Nordisk A/S (NYSE: NVO) announced it has filed a lawsuit against Eli Lilly and...
Junshi Biosciences Receives NMPA Acceptance for Toripalimab Expanded Indication in Resectable Stage II–III NSCLC
Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the National Medical Products Administration (NMPA) has...
Gilead and Merck to Present Phase 3 ISLEND Trial Data for Once-Weekly Oral HIV Regimen at AIDS 2026 Conference
Gilead Sciences, Inc. (NASDAQ: GILD) and Merck & Co., Inc. (MSD; NYSE: MRK) announced that...
Alebund Pharmaceuticals Initiates Global Phase IIb Trial of AP306, First-in-Class Oral Pan-Phosphate Transporter Inhibitor for Hyperphosphatemia
Alebund Pharmaceuticals (HKG: 9637) announced that the first patient has been randomized and dosed in...